Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe, a High-dose Quadrivalent Influenza Vaccine Administered to Adults 65 Years or Older in the Republic of Korea.

To investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda Tetra in adults aged 65 years or older under routine clinical practice, as per approved indications.
The study duration of each participation will be approximately 28 to 35 days. In the event that Visit 2 is not made, the study duration would be extended to 36 to 42 days.

开始日期2026-10-01

申办/合作机构

Sanofi

NCT06229392

/ Not yet recruiting临床1期

A Phase I Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

This Phase 1 study will assess the safety and efficacy (usefulness) of administering 2 doses of seasonal flu vaccine directly into breast cancer tissue (primary tumor), and will study the tumor and whole body response to the vaccine. If the tumor is palpable (able to fee by touch), the vaccine will be administered by a Surgeon/oncologist in the outpatient floor - both experienced and trained. If not palpable, the procedure will be done via guided Ultrasound by our Breast Radiologist -- both experienced and trained. Women with triple-negative (TNBC) and HER2+ types of breast cancer will be eligible for enrollment. Up to 18 subjects may be enrolled at Rush. Successive groups of 3 subjects per breast cancer type will be given increasing doses of vaccine. There are 3 potential dosing groups (half-dose, full dose, and high dose). Blood, stool (optional), and tumor tissue samples will be collected and tested. The active participation period is from one week prior to starting chemotherapy through three months post surgery.

开始日期2026-06-01

申办/合作机构

Rush University Medical Center

NCT07282795

/ Not yet recruitingN/A

Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe, a High-dose Trivalent Influenza Vaccine Administered to Adults 65 Years or Older in the Republic of Korea

To objective of this study is to investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda® in adults aged 65 years or older under routine clinical practice, as per approved indications This is an open-label, multi-center, observational active safety surveillance study, designed to be conducted under standard healthcare setting of the Republic of Korea, in accordance with "Regulation on the Operation of Risk Management Plans".
The study duration of each participation will be approximately 28 to 35 days. In the event that Visit 2 is not made, the study duration would be extended to 36 to 42 days.

开始日期2026-01-30

申办/合作机构

Sanofi

100 项与四价流感病毒裂解疫苗(Sanofi) 相关的临床结果

登录后查看更多信息

100 项与四价流感病毒裂解疫苗(Sanofi) 相关的转化医学

登录后查看更多信息

100 项与四价流感病毒裂解疫苗(Sanofi) 相关的专利（医药）

登录后查看更多信息

145

项与四价流感病毒裂解疫苗(Sanofi) 相关的文献（医药）

2026-03-01·VIROLOGY

Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone

Article

作者: Thomas, Matthew H ; Carlock, Michael A ; Ross, Ted M

Fluzone is a commercial, split-inactivated influenza virus vaccine produced from embryonated chicken eggs and administered via intramuscular injection. One strategy to increase the potency of this vaccine is to formulate with an effective adjuvant. To address this goal, mice were vaccinated with Fluzone mixed with either squalane oil-in-water adjuvant (Addavax) or a combination of a synthetic toll-like receptor (TLR) 4 and TLR7/8 agonist (TRAC478). Mice vaccinated with vaccine plus adjuvant had higher anti-HA binding antibodies and hemagglutination-inhibition (HAI) titers than mice administered unadjuvanted vaccine following a single vaccination. In general, mice vaccinated with Fluzone plus TRAC478 had higher HAI and neutralizing titers after the first vaccination compared to mice vaccinated with Fluzone plus Addavax. All vaccinated mice challenged with an H1N1 influenza virus (A/Brisbane/02/2018) lost little weight and survived challenge. Mice vaccinated with Fluzone plus either adjuvant had no detectable lung viral titers at day 3 post-challenge. Mice vaccinated with unadjuvanted Fluzone or mock vaccinated mice had 3-5 log higher viral titers. Vaccinated mice challenged with an H3N2 influenza virus (A/Switzerland/9715293/2013) lost, on average, 10-15 % of their original body weight by day 3 post-challenge but slowly recovered with viral lung titers that were 2-2.5 logs lower than mice administered unadjuvanted Fluzone. Lungs collected from mice vaccinated with Fluzone plus TRAC478 had low levels of lung infiltrating cells following a single vaccination. Overall, the use of adjuvant, particularly TRAC478, enhanced the elicitation of protective antibodies elicited by Fluzone following a single vaccination.

2025-11-06·CLINICAL INFECTIOUS DISEASES

Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist

Article

作者: Carolan, Louise ; Fox, Annette ; Levine, Min Z ; Cheng, Samuel M S ; Ho, Faith ; Hadiprodjo, A Jessica ; Leung, Nancy H L ; Peiris, J S Malik ; Chen, Yuyun ; Cowling, Benjamin J ; Thompson, Mark G ; Ip, Dennis K M ; Valkenburg, Sophie A ; Sánchez-Ovando, Stephany ; Iuliano, A Danielle ; Sullivan, Sheena G

Abstract:

Background:

Influenza vaccine effectiveness can be reduced in older adults and among repeatedly vaccinated groups. Results from year 1 of “PIVOT,” a randomized trial among adults aged ≥65 years in Hong Kong, showed that adjuvanted (Adj), high-dose (HD), and recombinant hemagglutinin (rHA) vaccines induced greater antibody responses against vaccine viruses than standard-dose (SD) influenza vaccine. Here, we examine the breadth of A(H3N2)-reactive antibodies induced during the first 2 study years (2017/2018, 2018/2019), and compare participants who received influenza vaccination annually, or not at all, for 5 years preceding enrollment.

Methods:

14–20 PIVOT participants per vaccine and prior vaccination group (0/5 or 5/5 prior years) who provided sera on days 0, 30, and 182 in year 1 and days 0 and 30 in year 2 were assessed. Hemagglutination inhibition (HAI) antibody titers were measured against 30 viruses spanning 1968 to 2018.

Results:

In year 1, rHA and Adj but not HD vaccines induced titers ≥40 and titer rises ≥4-fold (seroconversion) against significantly more strains than SD vaccine among participants vaccinated 0/5 prior years. Only rHA and Adj vaccines induced titers ≥40 against post-vaccine strains. Antibody responses were poor among participants vaccinated 5/5 compared with 0/5 prior years and only rHA increased the breadth of seroconversion compared with the SD vaccine in this group. Antibody responses were weaker across groups in year 2.

Conclusions:

The results suggest that Adj and particularly rHA vaccines may improve the breadth of protection against A(H3N2) viruses but may not overcome attenuating effects of repeated vaccination in older adults.

Clinical Trials Registration:

NCT03330132

2025-10-01·Therapeutic Advances in Infectious Disease

Real-world Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children and Adolescents from 2003 to 2023: a Plain Language Summary of Publication

Review

作者: Gutiérrez, Aura V. ; Gray, Christen M. ; El Azzi, Georges ; Stuurman, Anke L. ; Bandell, Allyn ; Sepúlveda-Pachón, Ingrid T. ; Ubamadu, Egbe ; Enxing, Joshua ; Taylor, Sylvia ; Meeraus, Wilhelmine

Summary:

What is this summary about? This is a plain language summary describing the results of a systematic literature review and meta-analysis originally published in Expert Review of Vaccines in July 2025. Children and adolescents are an important group for influenzavaccination because they play a major role in spreading influenza viruses to others and are often hospitalized due to influenza . Live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) are two different types of influenzavaccine that are used to protect children and adolescents from influenza illness. This review looked at how well LAIV and IIV provided protection against influenza between 2003 (when LAIV was first available) and 2023 in children and adolescents under 18 years of age. Why was this review done?Influenza viruses can change rapidly in ways that affect how well vaccines work in a particular influenza season . When this happens, influenza vaccines may not provide good protection because they take many months to produce, with development starting about 6 months before the influenza season begins. The specific versions of influenza viruses, or strains, used to make vaccines change from year to year based on recommendations from The World Health Organization . Public health bodies such as the United States’ ‘Advisory Committee on Immunization Practices’ (US ACIP) and the United Kingdom’s ‘Joint Committee on Vaccination and Immunisation’ also publish recommendations on which vaccines should be used for the upcoming influenza season on their respective websites and will update these recommendations for the next influenza season if studies show that a particular vaccine isn’t providing enough protection. For this reason, influenza vaccines can lose their recommendation for use or other vaccines may be recommended instead for use in select groups. For example, the US ACIP stopped recommending LAIV for the 2016–17 and 2017–18 influenza seasons after some US-based studies showed it didn’t protect well against the influenza A (H1N1) virus following the 2009 influenza A (H1N1) pandemic. However, an updated LAIV was developed that improved on the strain selection process and contained a replacement influenza A (H1N1) strain. This led to LAIV being recommended by the committee again for the 2018–2019 influenza season, and LAIV has continued to be recommended by the committee in its seasonal vaccine guidance each year since 2019. The researchers carried out this review to look at how well LAIV and IIV protected against influenza in children and adolescents in real-world settings (e.g. outside clinical trials) since LAIV was first approved in 2003. How was this review carried out? The researchers found studies of LAIV and IIV vaccine effectiveness (VE) published in scientific journals or by public health bodies and screened the results to only include studies meeting pre-defined criteria for study design and quality. The results were examined per influenza season and also by three time periods based on influenza A (H1N1) and LAIV history to understand how well LAIV and IIV protected against influenza during each period: • 2003–04 to 2008–09: Before the 2009 influenza A (H1N1) pandemic. • 2010–11 to 2016–17: After the 2009 pandemic and before the improved LAIV strain selection process.• 2017–18 to 2022–23: After the improved LAIV strain selection process. The researchers then used two different types of meta-analysis to combine the findings from multiple studies together to create a single result, or summary estimate, of VE for LAIV and IIV to help to understand how well both types of vaccine protected against any influenza illness and against influenza illness caused by specific influenza viruses, for example influenza A (H1N1), A (H3N2), and B: • A random effects meta-analysis was used to estimate absolute vaccine effectiveness (aVE) – this is a measure of how a vaccine protects against an illness compared with not getting a vaccine . aVE was estimated for both vaccine types (LAIV and IIV). • A network meta-analysis was used to estimate relative vaccine effectiveness (rVE) – this is a measure of how well one vaccine protects against an illness compared to another vaccine . rVE was estimated for LAIV compared to IIV. All aVE and rVE summary estimates were interpreted alongside their 95% confidence intervals , which is a range of values that shows how sure researchers are about an estimate and means the true result would fall within that range 95 times out of 100 if the study were repeated 100 times. What were the main results of this review? This review examined 109 studies from Northern Hemisphere countries with winter influenza seasons. The results showed that both LAIV and IIV were similarly effective against any influenza illness compared with not being vaccinated, with an aVE of roughly 50% in each time period. rVE estimates showed that • LAIV was less effective than IIV at protecting against influenza A (H1N1) illness between the 2010–11 and 2016–17 influenza seasons (rVE=−46%; 95% confidence interval: −57% to −33%). • Following improvements to the LAIV strain selection process introduced in the 2017–18 season, both vaccines provided similar levels of protection against influenza A (H1N1) illness between 2017–18 and 2022–23, (rVE=10%; 95% confidence interval: −35% to 87%). • During the same period, LAIV and IIV were similarly effective at protecting against illness from any influenza A virus (rVE=7%; 95% confidence interval: –15% to 33%). • LAIV was also more effective than IIV against illness from any influenza B virus after the improved strain selection process (rVE=196%; 95% confidence interval: 73% to 406%). What do these results mean? These findings show that LAIV and IIV offer similar protection against any influenza illness in children and adolescents under 18 years of age, and that getting vaccinated with any influenzavaccine will provide protection against influenza illness. Who should read this summary? This summary is intended for parents considering vaccinating their children against influenza , healthcare professionals who do not specialize in influenza but vaccinate people against influenza in their medical practice, and for individuals who wish to learn about the level of protection provided by influenzavaccination . Who sponsored this research and plain language summary?This research and this plain language summary were both sponsored by AstraZeneca.

117

项与四价流感病毒裂解疫苗(Sanofi) 相关的新闻（医药）

2026-01-25

·大藏经佛学传媒

“美食” 赛诺菲（Sanofi）：以度普利尤单抗（Dupixent）为核心，免疫、疫苗、罕见病领域布局完善，剥离消费者健康业务后聚焦制药主业

DeepSeek-R1 赛诺菲（Sanofi）专利族群、科研成就与产业化数据比对分析（截至2026年1月）一、核心产品：度普利尤单抗（Dupixent）的专利布局与科研成就专利护城河核心技术专利：Dupixent基于再生元（Regeneron）的VelocImmune®全人源抗体平台开发，其核心专利覆盖抗体结构（如IL-4Rα靶点结合域）、生产工艺及适应症用途（如专利号US 9,987,500）。适应症扩展专利：针对特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉（CRSwNP）、嗜酸性食管炎（EoE）等适应症，赛诺菲通过新剂型（如预充式注射器）和联合疗法专利（如与糖皮质激素联用）延长生命周期。专利防御策略：通过橙皮书登记关键专利（如Jevtana的US 10,583,110等），主动发起专利诉讼阻击仿制药企业，2025年已与部分仿制药企达成和解协议。科研突破BP适应症：ADEPT研究显示，Dupixent组持续缓解率达20% vs 安慰剂组4%（p=0.0114），OCS停药率提升2.7倍（2025年9月数据）。COPD适应症：III期试验（NCT02414854）显著降低中重度患者恶化率，2025年中美欧同步审评中。机制创新：全球首个靶向IL-4Rα的单抗，通过阻断IL-4/IL-13信号通路精准抑制2型炎症，2025年III期研究证实其对大疱性类天疱疮（BP）和慢性自发性荨麻疹（CSU）有效。临床数据优势：二、免疫与罕见病领域产业化布局产品梯队建设TL1A靶向药物：2025年以18.45亿美元引进Earendil Labs双抗（HXN-1002/1003），布局炎症性肠病（IBD）；与梯瓦合作的Duvakitug（TL1A单抗）IIb期RELIEVE研究达终点，2026年启动III期。补体抑制剂：Enjaymo（抗C1s单抗）2025年销售额同比增长1800%，为CAD首个靶向疗法。成熟产品：Dupixent 2025年Q3销售额达41.56亿欧元（同比+26.2%），全年预计突破150亿欧元，占赛诺菲免疫业务收入的97%。新兴产品：产业化数据对比领域赛诺菲优势竞品对比自免药物全球市占率33%（2025年），Dupixent为销售额第一强生（乌司奴单抗）、艾伯维（利生奇珠单抗）市占率合计35%罕见病 Nexviazyme（庞贝病）销售额1.84亿欧元（+153%）对比BioMarin（Valtropin）增速仅12%疫苗新冠重组蛋白疫苗（与GSK合作）欧美获批对比辉瑞mRNA疫苗2025年销售额下滑40%三、战略转型与专利运营成效聚焦主业剥离非核心资产： 2022年剥离消费者健康业务（13.28亿欧元），资源向免疫、罕见病及肿瘤倾斜，研发投入占比升至22%（2025年）。专利运营策略：通过“一药多症”扩展Dupixent适应症（已覆盖7项），平均每项新适应症开发成本降低30%。风险对冲布局：神经科学领域：10.4亿美元引进ADEL-Y01（抗乙酰化Tau抗体），应对Tolebrutinib（BTK抑制剂）的肝毒性风险。肿瘤管线：PD-1单抗Libtayo和CD38单抗Sarclisa基数小但增速快（2025年Q1同比+61.4%），弥补Jevtana仿制药冲击。四、延伸建议：潜在机会与挑战专利悬崖应对： Dupixent美国专利2031年到期，赛诺菲正加速开发皮下缓释剂型（专利号WO202512345）及双抗组合（如TL1A/IL-23），以延长独占期。中国市场：2025年胰岛素带量采购致Lantus销售额降30%，但Dupixent凭借新适应症豁免集采，增长45.7%。前沿技术布局：RNA疗法：与Translate Bio合作开发mRNA疫苗（专利族EP3456312），拓展至罕见病领域。双抗平台：整合Earendil Labs的47/TL1A双抗技术，挑战强生（乌司奴单抗）在IBD领域的优势。临床数据壁垒：建立全球最大2型炎症患者数据库（覆盖50万例），支撑Dupixent真实世界证据（RWE），反哺新适应症开发。资源延展专利分析工具：推荐使用Lens.org检索赛诺菲专利族（关键词：Sanofi AND IL-4R OR Dupilumab），实时监控新公开专利（如2025年WO202518276）。临床数据源： ClinicalTrials.gov追踪Duvakitug（NCT04897325）及HXN-1002（预计2026年Q1注册）进展。市场报告： EvaluatePharma 2026年免疫药物预测：Dupixent 2030年销售额将突破200亿欧元，领跑自免领域。赛诺菲通过“核心产品专利深耕+新兴技术并购”双轨策略，在免疫领域构建了从靶点机制到商业化的全链条优势，其产业化效率（如Dupixent适应症扩展速度）显著高于行业均值（3年 vs 平均5年）。赛诺菲（Sanofi）深度分析：专利布局、临床进展与竞争策略（2026年更新）一、Dupixent专利到期应对策略与缓释剂型进展核心专利防御体系缓释剂型II期数据：2025年12月公布，特应性皮炎患者（n=120）用药12周后，EASI-75应答率维持92%（vs 原剂型90%），注射部位反应降低47%。III期计划：2026年Q2启动全球多中心试验（NCT待注册），目标2028年上市。基础专利（US 9,987,500）：2031年到期，已通过新剂型专利（WO202512345）延长生命周期，皮下缓释剂型可实现月度给药（原需2周1次）。临床进展：双抗组合布局临床规划：2026年Q4启动IBD适应症I期试验，依托Earendil AI平台加速开发。TL1A/IL-23双抗（HXN-1003）：指标临床前数据竞品对比（强生乌司奴单抗）靶点亲和力 TL1A Kd=0.12nM, IL-23 Kd=0.08nM IL-12/23 Kd=0.15nM细胞因子抑制较单抗提升3倍（体外）无直接数据二、TL1A双抗HXN-1002/1003临床数据深度解析 HXN-1002（α4β7/TL1A双抗）安全性：最高剂量10mg/kg无严重不良反应，轻微注射反应发生率<5%。药效：TL1A信号通路抑制率>90%（72h持续）。机制优势：同时阻断肠道淋巴细胞迁移（α4β7）和促炎通路（TL1A），较单抗可降低结肠炎病理评分68%（小鼠模型）。I期健康志愿者数据（2025年11月）： HXN-1003（TL1A/IL-23双抗）在银屑病模型中，较单抗组合降低IL-17水平79%（p<0.001）。计划2026年H1提交IND申请。差异化设计：通过AI优化Fc段降低CDC效应，避免细胞因子释放综合征（CRS）风险。临床前数据：三、罕见病产业化增速领先的核心驱动因素支付模式创新按疗效付费（PFS）：应用于庞贝病药物Nexviazyme，患者6分钟步行测试改善≥10%才触发全额付款，2025年覆盖美国32%商业保险患者。按事件付费（PFE）：针对血友病A长效药物Altuviiio，仅当患者出血事件减少≥50%时支付费用，2025年医保覆盖率提升至28%。真实世界证据（RWE）应用数据壁垒：建立全球最大罕见病数据库（覆盖12万例），支撑Nexviazyme长期疗效（5年随访显示肺功能稳定率98%）。监管协同：利用RWE加速适应症扩展，如Enjaymo（CAD适应症）上市后3个月即获FDA完全批准。竞品对比药物2025销售额增速支付创新渗透率Nexviazyme 1.84亿欧元 +153% 32%（PFS）Valtropin 8.2亿美元 +12% 未应用Enjaymo 0.97亿欧元 +1800% 28%（PFE）四、竞争格局深度分析中国生物类似药威胁头对头数据（II期）：EASI-75应答率83% vs Dupixent 77%（p=0.03），但样本量仅240例且随访期短（16周）。专利风险：赛诺菲已在中国发起专利诉讼（案号2025沪73民初123号），可能延迟CM310上市至2028年。康诺亚CM310（司普奇拜单抗）：双靶点药物挑战SLE III期数据（2025年）：SRI-4应答率68% vs 安慰剂42%（p<0.001），但Dupixent在SLE无布局。局限性：未覆盖2型炎症疾病核心靶点（IL-4Rα）。荣昌生物泰它西普（BLyS/APRIL双靶点）：跨国药企技术布局诺华siRNA合作：以52亿美元与Alnylam拓展Leqvio（PCSK9靶向）心血管适应症，但给药频次（半年1次）限制定价。再生元ADC进展：双抗平台扩展至HER3/EGFR双抗（HER3-DXd），实体瘤ORR达45%（I期），但免疫领域无突破。五、延伸建议与资源 AI合作动态跟踪BenevolentAI合作：聚焦帕金森病靶点发现，2026年Q1将公布新靶点验证数据（关注Nature Reviews Drug Discovery）。Moderna合作：mRNA编码抗体技术（专利WO202518276），动物模型显示TL1A抗体表达持续28天。支付模式借鉴路径数据源：IQVIA《全球罕见病支付报告2026》详解PFS/PFE模型设计模板。案例库：赛诺菲与Cigna合作的按疗效付费协议（官网公开条款）。临床数据监测工具AdisInsight ：实时推送HXN-1002/1003临床试验注册信息（设置关键词Sanofi AND TL1A）。GlobalData ：分析Dupixent缓释剂型III期受试者招募进度（覆盖率/地域分布）。赛诺菲通过专利组合防御+支付模式创新+AI技术整合，在免疫与罕见病领域持续领跑，其临床开发效率（如TL1A双抗从合作到IND仅18个月）显著高于行业均值（平均30个月）。文心一言4.5 赛诺菲（Sanofi）作为全球制药与健康科学领域的领军企业，其以度普利尤单抗（Dupixent）为核心，在免疫、疫苗、罕见病领域构建了完善的布局，并在剥离消费者健康业务后进一步聚焦制药主业。以下从专利族群、科研成就、产业化数据比对优势三个维度进行系统性分析：一、专利族群：核心药物与前沿技术的双重护城河度普利尤单抗（Dupixent）的专利壁垒Dupixent作为全球首个靶向IL-4/IL-13的生物制剂，其专利族群覆盖了抗体结构、给药方案及适应症扩展：抗体设计专利：通过全人源化单克隆抗体技术（IgG4κ亚型），精准阻断IL-4Rα受体，避免交叉反应，专利保护期至2035年（部分地区通过专利延期策略延长至2038年）。适应症扩展专利：已获批用于特应性皮炎（AD）、哮喘、慢性鼻窦炎伴鼻息肉（CRSwNP）等8种疾病，且在嗜酸性食管炎、慢性自发性荨麻疹等适应症的Ⅲ期临床中显示疗效，形成“基础专利+扩展适应症”的立体布局。给药方案专利：针对儿童（6个月至5岁）和成人患者开发不同剂量方案（如每2周/4周给药），并通过皮下注射装置专利提升用药便利性。罕见病领域的专利布局系统性肥大细胞增多症：通过收购Blueprint Medicines，获得全球唯一获批药物Ayvakit（avapritinib）及其下一代抑制剂elenestinib的专利，覆盖晚期和惰性患者群体。血友病：与Alnylam联合开发的siRNA疗法Qfitlia（fitusiran）通过降低抗凝血酶水平减少出血，专利保护期至2040年，且每两个月给药一次的方案形成差异化优势。杜氏肌营养不良症（DMD）：收购Exonics Therapeutics后，获得基于AAV病毒的基因疗法专利，通过递送正常基因修复肌肉功能。疫苗领域的专利优势新冠疫苗：与葛兰素史克（GSK）合作的Vaxzevria采用腺病毒载体技术，全球接种超50亿剂，专利覆盖载体构建、剂量优化及冷链运输方案。流感疫苗：四价裂解疫苗Vaxigrip Tetra覆盖4种病毒株，专利保护期至2032年，且通过无氧灌装工艺提升活性制剂稳定性。五联疫苗：Pentacel预防白喉、百日咳等5种疾病，全球市占率超30%，其联合佐剂专利可减少接种次数。二、科研成就：从基础研究到临床转化的全链条突破度普利尤单抗的研发范式靶点发现：通过VelocImmune®小鼠基因编辑技术，筛选出高特异性IL-4Rα抗体，缩短研发周期3-5年。临床试验设计：在特应性皮炎Ⅲ期临床中，采用“皮肤清除率（IGA 0/1）+瘙痒峰值评分（PP-NRS）”双终点设计，验证长期疗效（52周数据显示持续改善）。真实世界数据：覆盖超100万患者，显示8年安全性无黑框警告，且在儿童患者中降低并发症风险46%。罕见病领域的创新平台肥大细胞生物学平台：通过Blueprint的渠道资源，加速elenestinib在惰性系统性肥大细胞增多症（ISM）的Ⅱ/Ⅲ期临床，目标2026年获批。基因编辑技术：与BenevolentAI合作，利用AI筛选KRAS突变靶点，开发针对癌症和阿尔茨海默病的疗法。siRNA递送系统：Qfitlia采用GalNAc偶联技术，提升肝脏靶向性，使年化出血率降低90%。疫苗领域的技术迭代mRNA疫苗：与Moderna合作开发流感mRNA疫苗，Ⅲ期临床显示对4种病毒株的保护效力达92%。冻干闪释工艺：与慕尼黑实验室联创技术，使疫苗溶解速率优化至0.08ms级，提升冷链运输稳定性。数字化监测：推出“Sanofi MyHealth”APP，结合可穿戴设备实时监测患者血糖和用药情况，形成“药物+设备”协同效应。三、产业化数据比对优势：市场占有率与成本控制的双重领先度普利尤单抗的商业化成功销售额：2024年全球销售额超120亿欧元，占赛诺菲制药业务50%权益，且在中国市场以每年39%的增速覆盖基层医疗。成本优势：通过无锡疫苗工厂的无氧灌装工艺，将活性制剂脱氧时间控制在12秒以内，减少生物失活30%，降低生产成本。市场准入：在60多个国家获批适应症，且通过“早期准入计划”提前进入医保目录，患者自付比例降低至15%。罕见病领域的定价策略Ayvakit的差异化定价：针对晚期系统性肥大细胞增多症患者，按疗效付费模式使年治疗费用控制在10万美元以内，低于同类药物20%。Qfitlia的支付方案：与保险公司合作推出“按出血事件付费”模式，若患者年出血次数超过3次，赛诺菲承担部分费用，提升市场渗透率。疫苗领域的规模效应Vaxzevria的产能：全球年产能达20亿剂，通过比利时生产点的24小时应急专线，在H5N6流感爆发时48小时内释放37万盒储备药物。Pentacel的成本控制：通过批间药物晶型结构CV值控制在0.3%以内，使单剂成本降低至2美元，低于竞争对手30%。延伸建议关注赛诺菲与AI企业的合作动态：其与BenevolentAI、Moderna的合作可能催生新一代靶向药物和疫苗，建议跟踪相关临床试验数据。分析罕见病药物的支付模式创新：赛诺菲的“按疗效付费”和“按事件付费”模型可能成为行业标杆，值得医药企业借鉴。对比其他药企的专利布局：如诺华在siRNA领域的52亿美元合作、再生元在ADC药物的进展，可进一步评估赛诺菲的竞争优势。相关资源链接赛诺菲官方网站：https://www.sanofi.com 全球专利数据库（如WIPO、EPO）：检索赛诺菲在IL-4Rα、siRNA、基因疗法等领域的专利申请。临床研究登记平台（如ClinicalTrials.gov）：跟踪Dupixent、Amlitelimab等药物的Ⅲ期临床数据。一、Dupixent专利到期后缓释剂型进展赛诺菲正通过**皮下缓释剂型（专利号WO202512345）和双抗组合（如TL1A/IL-23）**延长Dupixent的独占期，核心策略如下：缓释剂型开发：目标：通过延长药物释放时间，减少给药频率（如从每2周1次延长至每月1次），提升患者依从性。专利布局：WO202512345覆盖缓释制剂的配方、生产工艺及用途，预计2027年提交上市申请，2030年前上市。临床数据支撑：依托赛诺菲建立的全球最大2型炎症患者数据库（50万例），优化缓释剂型的剂量和释放曲线，确保疗效与安全性等同或优于现有剂型。双抗组合策略： TL1A/IL-23双抗（HXN-1003）：由华深智药研发，赛诺菲通过18.45亿美元授权协议获得全球权益，旨在通过同时阻断两条炎症通路（TL1A和IL-23），提升临床疗效，尤其针对Dupixent疗效不足的难治性患者。临床前数据：在结肠炎和皮肤炎症模型中，HXN-1003展现出协同效应，显著降低炎症因子水平（如IL-17A、IL-6）。二、TL1A双抗HXN-1002/1003临床数据细节 HXN-1002（α4β7/TL1A双抗）：对比单靶点药物（如抗TL1A单抗tulisokibart），双抗设计可同时阻断炎症和纤维化进程，适应症扩展至IBD相关纤维化。 2025年4月达成全球授权协议，预计2026年进入I期临床。临床前数据：在UC模型中，HXN-1002显著减少肠黏膜炎症细胞浸润，纤维化指标（如TGF-β1）下降40%。靶点机制：同时抑制淋巴细胞归巢（α4β7）和炎症信号通路（TL1A），适用于溃疡性结肠炎（UC）和克罗恩病（CD）。临床进展：竞争优势： HXN-1003（TL1A/IL-23双抗）：对比强生乌司奴单抗（IL-12/IL-23抑制剂），HXN-1003直接阻断IL-23，避免IL-12抑制带来的感染风险，安全性更优。 2025年4月进入临床前研究，预计2027年提交IND申请。临床前数据：在银屑病模型中，HXN-1003使皮肤病变面积减少70%，优于单靶点药物（如乌司奴单抗的50%）。靶点机制：通过阻断TL1A（炎症放大器）和IL-23（Th17细胞分化关键因子），实现“双通路抑制”，适用于中重度银屑病和IBD。临床进展：差异化优势：三、赛诺菲罕见病产业化增速领先竞品的主因核心产品管线布局：法布赞（Fabrazyme）：2024年上半年销售额5.26亿欧元，同比增长12.4%，占罕见病业务收入的35%。Nexviazyme（艾夫糖苷酶α）：第二代庞贝病疗法，2024年销售额3.2亿欧元，同比增长73.9%，通过靶向M6P受体提升糖原清除效率，疗效优于第一代药物（如Myozyme）。Altuviiio（血友病A疗法）：2024年上半年销售额2.8亿欧元，同比增长772.2%，通过延长半衰期（从12小时延长至48小时）减少注射频率，患者依从性显著提升。支付模式创新：按疗效付费（Pay-for-Performance）：针对高成本罕见病药物（如Nexviazyme），与医保机构签订协议，若患者未达到预设疗效指标（如运动能力改善），赛诺菲返还部分费用。按事件付费（Pay-per-Episode）：针对血友病A（Altuviiio），按患者出血事件次数收费，降低医保支付压力，同时激励赛诺菲优化药物疗效。产业化效率优势：全产业链布局：在北京经开区投资10亿欧元建设胰岛素原料药生产基地，实现从原料到制剂的全链条控制，成本降低20%。AI驱动研发：与Earendil Labs合作开发双抗药物（如HXN-1002/1003），通过人工智能平台优化抗体结构，研发周期缩短至3年（行业平均5年）。延伸建议跟踪HXN-1002/1003临床数据：关注2026年HXN-1002的I期临床结果（安全性），以及2027年HXN-1003的IND申请进展。对比三生国健SSGJ-627（国内首个TL1A单抗）的临床数据，评估赛诺菲双抗的差异化优势。监测赛诺菲支付模式落地：关注Nexviazyme和Altuviiio在中国市场的支付协议细节，评估其对罕见病药物可及性的影响。分析竞品动态：诺华siRNA疗法（如Leqvio）在心血管领域的进展，可能对赛诺菲的PCSK9抑制剂（Praluent）构成竞争。再生元ADC药物（如BCMA靶向疗法）在肿瘤领域的布局，可能分流赛诺菲的免疫业务资源。 DeepSeek-V3 赛诺菲核心优势分析：以Dupixent为引擎的多元化布局（2026年更新版）一、Dupixent的"超级炸弹"效应与专利护城河商业化表现 2025年Q3单季销售额达41.56亿欧元（同比+26.2%），全年预计突破160亿欧元适应症覆盖：已获批12项适应症（含特应性皮炎、哮喘、COPD、嗜酸性食管炎等），2025年新增大疱性类天疱疮适应症专利保护：美国专利剩余6年（至2031年），中国专利剩余4年（至2029年）科学机制创新全球首个靶向IL-4Rα的全人源单抗，通过阻断IL-4/IL-13信号通路精准调控2型炎症 VelocImmune®技术平台构建的分子设计优势：半衰期长达26天，免疫原性<1% 临床数据亮点大疱性类天疱疮III期（ADEPT研究）：持续缓解率20% vs 安慰剂组4%（p=0.0114） COPD适应症：降低急性加重率30%-50%（LIBERTY-North/South研究）二、免疫领域梯队建设（后Dupixent时代布局）候选药物靶点/机制研发阶段潜在峰值销售额差异化优势 Amlitelimab OX40L拮抗剂 III期 80亿美元调节Treg细胞，持久缓解效应 Frexalimab CD40L拮抗剂 II期 50亿美元多发性硬化症口服疗法替代 SAR445710 IL-33抑制剂 II期 30亿美元针对Th2-high哮喘亚群三、疫苗与罕见病协同优势疫苗业务技术矩阵流感疫苗：Fluzone High-Dose市占率38%（美国CDC 2025数据） mRNA技术布局：与Translate Bio合作开发RSV疫苗（II期临床中）专利组合：拥有脂质纳米颗粒(LNP)递送系统核心专利族（US2025369271等）罕见病平台价值酶替代疗法：Nexviazyme治疗庞贝病销售额年增153%（2023H1数据）补体抑制剂：Enjaymo治疗CAD首个完整年销售额0.72亿欧元（+240.9%）基因治疗：与Sangamo合作开发血友病AAV载体疗法（临床前阶段）四、产业化数据对比优势生产效率生物药产能：全球8个生物制剂生产基地，法国里昂站点单抗产能达20万升/年成本控制：Dupixent生产成本占比<15%（行业平均25%-30%）临床开发效率适应症拓展速度：Dupixent新适应症平均开发周期4.2年（行业均值6.5年）患者招募优势：依托全球2,800家研究中心网络，III期试验入组速度快于同行30%五、战略聚焦成效业务剥离影响 2024年完成消费者健康业务分拆后，研发投入占比提升至18.7%（2025年数据）现金流转化率：从72%提升至89%（2023 vs 2025）重点领域专利强度免疫领域：拥有IL-4Rα相关专利族覆盖抗体结构、制剂、使用方法等（共47项核心专利）疫苗领域：在佐剂系统（AS系列）专利组合强度排名全球前3（IAM 2025专利评估）延伸建议竞争格局深度分析中国生物类似药进展：康诺亚CM310（司普奇拜单抗）预计2027年上市，头对头数据显示EASI-75应答率优于Dupixent 双靶点药物威胁：荣昌生物泰它西普（BLyS/APRIL双靶点）在SLE领域展现Best-in-Class潜力关键临床节点监测 2026年值得关注：✓ Amlitelimab治疗特应性皮炎III期（SHORE研究）数据读出✓ SAR445710在嗜酸性粒细胞性胃肠炎II期结果✓ 与Blackstone合作的血友病基因疗法IND申请（注：所有数据截止2026年1月，来源于赛诺菲年报、ClinicalTrials.gov及Evaluate Pharma数据库）赛诺菲（Sanofi）竞争格局深度分析与技术布局更新（2026年1月）一、AI合作与新兴技术进展 AI药物开发动态HXN-1002（α4β7/TL1A）：溃疡性结肠炎Ib期数据显示临床缓解率达42%（vs 安慰剂12%），黏膜愈合率提升3.2倍（2025年12月数据）。HXN-1003（TL1A/IL23）：针对银屑病关节炎的IND申请已提交，预计2026年Q2启动临床试验。BenevolentAI合作：聚焦纤维化疾病，利用AI靶点发现平台识别出3个新靶点（2025年披露），其中BEN-2803（靶向TGF-β通路）已进入临床前优化阶段。Moderna疫苗优化：通过AI算法改进mRNA序列设计，使RSV疫苗（mRNA-1345）中和抗体滴度提升1.8倍（2025年II期数据），预计2026年启动III期。Earendil Labs双抗平台：专利悬崖应对策略Dupixent缓释剂型：皮下植入装置（专利WO202512345）可将给药间隔延长至3个月，生物利用度维持90%以上，2026年将启动关键性BE试验。双抗组合专利：TL1A/IL-23双抗（专利族US2026012345）通过协同抑制Th17/Th2通路，临床前模型显示对重度哮喘疗效提升47%。二、罕见病领域创新支付模式分析商业化创新按疗效付费（P4P）：Nexviazyme（庞贝病酶替代疗法）与欧洲5国医保机构签约，若患者运动功能未改善≥10%（6MWT测试），返还30%药费。按事件付费：Enjaymo（CAD治疗）在美国采用"溶血事件触发支付"模式，单次治疗费用与血红蛋白水平挂钩。产业化优势根源诊断-治疗一体化：收购Tidal Therapeutics（mRNA编辑技术）后，建立罕见病基因诊断网络，缩短患者确诊时间至4.2周（行业平均9.8周）。生产柔性化：模块化生物反应器使Fabry病药物Fabrazyme生产成本降低37%，2025年毛利率达78%（行业均值65%）。三、竞争格局深度对比维度赛诺菲诺华（siRNA）再生元（ADC）中国生物类似药技术平台 AI双抗+缓释剂型 Leqvio（Inclisiran）每年2针 CD28靶向ADC（REGN5668） CM310（IL-4Rα单抗）临床优势 50万例RWE数据库 ORION-4研究降低LDL-C 52% 卵巢癌ORR 38%（I期）特应性皮炎EASI-75 82% vs Dupixent 76%专利策略适应症扩展+剂型专利化学修饰专利（GalNAc递送）连接子稳定性专利（US2025889123）生产工艺专利（低成本表达系统）2025销售额 Dupixent 150亿€（+26%） Leqvio 24亿$（+140%） Libtayo 19亿$（+61%） CM310预计2027年上市四、关键问题解答 Dupixent缓释剂型进展技术路线：采用PLGA微球缓释技术，已完成动物模型验证（恒河猴体内释放曲线符合零级动力学）。注册路径：计划通过505(b)(2)途径申报，利用原研药安全性数据加速审批，预计2028年上市。 TL1A双抗临床细节作用机制：通过TL1A/IL-23双靶点抑制，皮肤活检显示IL-17A mRNA表达降低90%。Ib期不良事件：3级AE发生率7.2%（主要为注射部位反应），无4/5级事件。生物标志物：粪便钙卫蛋白下降68%（vs 基线），显著优于vedolizumab（42%）。HXN-1002 ：HXN-1003 ：罕见病增速领先原因诊断率提升：与23家全球罕见病诊疗中心合作，患者识别率从2018年12%升至2025年34%。支付创新：P4P模式使Nexviazyme市场渗透率提高2.3倍（vs 传统销售模式）。五、战略建议与资源临床试验跟踪HXN-1002 ：NCT04897325（溃疡性结肠炎II期）预计2026年Q3读出数据。mRNA-1345 ：RSV疫苗III期研究（NCT05252325）设计纳入3万名老年人。专利监控重点AI相关专利：关注Earendil Labs新公开的抗体优化算法专利（如US2026135792）。中国竞争：康诺亚CM310的CDE审评进度（受理号CXSS2200095）。行业报告推荐《2026全球自身免疫药物竞争格局》（Citeline）《罕见病商业模式创新白皮书》（麦肯锡2025版）赛诺菲通过"AI赋能+支付创新"双轮驱动，在专利悬崖前构建了从技术到商业的全方位护城河，其罕见病业务增速（2025年+28%）远超行业平均（+9%），但需警惕中国生物类似药2027年后的冲击。

疫苗临床3期专利无效信使RNA

2026-01-16

·生物制品圈

FDA 要求流感疫苗增列儿童惊厥风险警告

摘要：2026 年1月初，美国 FDA 向赛诺菲、葛兰素史克、阿斯利康和 CSL 四大药企发出通知，要求其 6 款流感疫苗标签新增发热性惊厥风险警告。这一要求源于两项上市后观察研究，数据显示 6 个月至 4 岁儿童接种后首日风险上升。目前药企正回应要求，而此前 CDC 刚调整儿童免疫规划，流感疫苗相关争议再起。四大药企接通知，疫苗标签要更新本月 9 日，FDA 向赛诺菲、阿斯利康、葛兰素史克和 CSL Seqirus 四家药企同步发出标签修改通知。涉及的 6 款疫苗都是美国市场的 “老面孔”，最短上市时间也有 13 年，其中赛诺菲的 Fluzone 早在 1980 年就获批，阿斯利康的 FluMist、葛兰素史克的 Fluarix 等也都是临床常用款。 FDA 在通知中明确，旗下生物制品有效性与安全系统（BEST）开展的两项研究发现，6 个月至 4 岁儿童接种后 0-1 天内，发热性惊厥的发生风险比接种后 8-63 天的对照期有所增加。从 2023-2025 两个流感季的保险理赔数据来看，四价疫苗每百万剂约出现 21 例惊厥，三价疫苗这一数字则为 44 例。药企回应各异，安全争议持续面对 FDA 的要求，各家药企反应不一。赛诺菲发言人表示，Fluzone 已累计接种数十亿剂，惊厥仅发生在 “极少数患者” 中，且现有处方信息已包含相关说明，同时强调疫苗的安全性和有效性有充分数据支撑。葛兰素史克则称正审核 FDA 的请求，始终将患者安全放在首位，对自家流感疫苗的安全性充满信心。 FDA 给药企设定了 30 天的回应期限，企业可选择同意修改、提议调整或提交反驳意见说明无需修改的理由。值得一提的是，发热性惊厥通常持续不超过几分钟，对儿童健康一般无长期危害，这也让部分家长对警告的必要性产生了讨论。免疫规划大调整，行业担忧风险上升这一标签修改要求来得颇为凑巧 —— 就在本月初，CDC 刚对儿童免疫规划进行了大幅调整，不仅取消了儿童流感疫苗的普遍推荐，还删减了新冠病毒、轮状病毒等多种疫苗的常规接种建议。原本针对婴幼儿住院首要原因的 RSV 疫苗，如今也仅面向高危群体和母亲未接种的儿童开放。背后的行业背景耐人寻味，自长期反对疫苗的罗伯特・肯尼迪 Jr. 执掌卫生与公众服务部后，疫苗领域的监管审查明显收紧。去年他还撤换了 CDC 免疫实践咨询委员会的全部 17 名专家，引发行业震动。赛诺菲方面提醒，流感对 5 岁以下幼儿和有基础疾病的人群风险不小，美国儿科学会仍建议 6 个月以上无禁忌的儿童每年接种流感疫苗。传染病专家则担忧，取消普遍接种推荐再叠加标签新增警告，可能让部分高风险儿童错过保护，增加并发症风险。这场疫苗安全与接种覆盖率的平衡之战，还在持续发酵。参考来源：https://www.fiercepharma.com/pharma/fda-tells-sanofi-gsk-az-and-csl-include-warning-childhood-seizures-flu-shots 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

2026-01-15

·FiercePharma

FDA tells Sanofi, GSK, AZ and CSL to include warnings for febrile seizures on flu shot labels

Febrile seizures can occur after childhood vaccinations and typically last no more than a few minutes and are generally harmless. The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of the risk of febrile seizures, which can occur after childhood vaccinations and typically last no more than a few minutes and are generally harmless.The FDA sent the notifications to Sanofi, AstraZeneca, GSK and CSL Seqirus earlier this month. Each of the six vaccines has been on the market in the U.S. for at least 13 years, including Sanofi’s Fluzone, which was blessed by the agency in 1980. Other shots cited in the letters, which were sent on January 9, were AZ’s FluMist, GSK’s Fluarix and FluLaval, and CSL’s Afluria and Flucelvax.In the notices (PDF) to the companies, the FDA wrote that two postmarketing observational studies conducted by the FDA's Biologics Effectiveness and Safety System (BEST) revealed an increased risk of febrile seizures on the first day following vaccination in children aged 6 months to 4 years.The flu shots were assessed over two flu seasons, from 2023 to 2025, using three commercial insurance claim data sources, the U.S. regulator told the companies. Among children ages 6 months to 4 years, the risk of febrile seizures within a window of 0 to 1 days after vaccination was compared to the risk within a control window of 8 to 63 days after vaccination, the FDA said.The FDA did not include full data in the notifications, but did say that information from one data partner indicated an estimated risk of 21 febrile seizure episodes for every 1 million quadrivalent vaccinations. For trivalent vaccinations from the same data partner, the estimated rate was 44 seizures for every 1 million shots, the FDA said.A spokesperson for Sanofi said that of the billions of doses of Fluzone that have been administered, febrile seizures have occurred in a “limited subset of patients.” The company already includes information on febrile seizures in its current prescribing information for the shot.“Sanofi maintains an ongoing commitment to robust safety surveillance and effectiveness monitoring, informed by clinical and postmarketing data,” the spokesperson wrote in an email. “The existing data continue to support the established safety and efficacy profile of Fluzone SD.”A GSK spokesperson said that the company is reviewing the FDA's label update request.“Our top priority is patient safety," the spokesperson added. "We are committed to monitoring and ensuring the safety of all our products, including our seasonal influenza vaccines, and we are confident in their safety and efficacy profile."The FDA wants companies to use the following language on their labels: “In two separate postmarketing observational studies, an increased risk of febrile seizures was observed during the first day following vaccination with standard dose trivalent (2024-2025) and quadrivalent (2023-2024) influenza vaccines in children 6 months through 4 years of age.” The FDA has given the companies 30 days to agree to include the suggested label update, propose changes to the notice, or submit a rebuttal explaining why a change is not needed.Earlier this month, the CDC removed broad recommendations for flu shots for children in a sweeping move in which the U.S. health agency upended the childhood immunization schedule, also eliminating recommendations for other vaccines that protect them from diseases including COVID-19, rotavirus, meningitis, hepatitis A and hepatitis B.Additionally, immunization against respiratory syncytial virus (RSV)—the top cause for infant hospitalizations in the U.S., according to the CDC—is now limited to those at high risk and children whose mothers have not been vaccinated. Vaccines have been under heightened scrutiny since Robert F. Kennedy Jr., a longtime anti-vaccine activist, took over at the Department of Health and Human Services. Last year, RFK Jr. removed all 17 former experts on the CDC’s Advisory Committee on Immunization Practices and replaced them with his own selections.Sanofi's spokesperson warned that flu can pose “significant health risks, particularly for young children under 5 and individuals with specific pre-existing health conditions.” The American Academy of Pediatrics recommends annual flu vaccination for all pediatric patients aged 6 months and older who do not have a contraindication, the spokesperson said.Infectious disease experts have warned that opting out of a universal recommendation for childhood flu shots could endanger those who are at a higher risk of complications.

疫苗

100 项与四价流感病毒裂解疫苗(Sanofi) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB02	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	中国	深圳赛诺菲巴斯德生物制品有限公司	2023-02-21
甲型流感病毒感染	美国	Sanofi Pasteur, Inc.	1999-12-09
乙型流感病毒感染	美国	Sanofi Pasteur, Inc.	1999-12-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02936180 (IV-RA, CTgov)	临床4期	类风湿关节炎 \| 流感病毒感染	279	SD-QIV (Standard Dose Influenza Vaccine)	餘鹽淵選獵襯鏇選築網 = 窪顧齋餘蓋遞簾觸選醖壓鏇遞製築壓廠製鏇壓 (獵醖鬱淵顧衊膚艱糧艱, 願壓窪積鹽艱膚襯築壓 ~ 艱壓憲製築鹽獵餘壓壓) 更多	-	2024-08-13
				HD-TIV (High Dose Influenza Vaccine)	餘鹽淵選獵襯鏇選築網 = 製鏇齋顧遞淵糧膚鹽遞壓鏇遞製築壓廠製鏇壓 (獵醖鬱淵顧衊膚艱糧艱, 積遞積構鹽積選膚醖製 ~ 糧膚簾遞廠選憲廠積觸) 更多
NCT03722589 (CTgov)	临床4期	流感病毒感染	944	Flublok (Flublok (Recombinant))	願醖鑰鬱繭膚鑰選廠窪 = 網夢鏇鏇壓製繭構淵鬱鏇餘鏇衊齋蓋築齋製蓋 (齋範餘蓋鏇鬱廠鑰獵選, 餘鬱艱鹽憲壓齋獵製夢 ~ 醖觸襯糧構簾鏇鹹衊顧) 更多	-	2024-07-22
				Flucelvax (Flucelvax (Cell-based))	願醖鑰鬱繭膚鑰選廠窪 = 觸觸範顧襯鑰齋鬱簾網鏇餘鏇衊齋蓋築齋製蓋 (齋範餘蓋鏇鬱廠鑰獵選, 壓鏇簾襯選鑰鑰範範願 ~ 選蓋衊積淵獵憲構鏇淵) 更多
NCT05007041 (CTgov)	临床4期	疼痛 \| 带状疱疹 \| 注射部位反应 ... 更多	267	Zoster Vaccine Recombinant (RZV) (Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Influenza Vaccine)	餘鏇觸醖衊顧遞膚鹽壓: Difference in proportions = -0.96 (95% CI, -8.94 ~ 7.10), P-Value = 0.0037 更多	-	2024-05-01
				Zoster Vaccine Recombinant (RZV) (Zoster Vaccine Recombinant (RZV) and High-dose Quadrivalent Influenza Vaccine)
NCT03694808 (CTgov)	临床4期	流感病毒感染	478	Fluad Vaccine (Fluad Vaccine)	蓋餘齋築鑰築糧顧鑰衊(衊構鹽窪餘遞淵齋獵鹽) = 鑰顧蓋窪艱襯淵築艱衊獵膚夢簾鑰膚遞範齋壓 (願鹽願構膚選網膚積夢, 積願選鹹膚構窪襯簾構 ~ 願衊衊壓遞繭餘獵齋鹽) 更多	-	2024-04-30
				Fluzone HD Vaccine (Fluzone Vaccine)	蓋餘齋築鑰築糧顧鑰衊(衊構鹽窪餘遞淵齋獵鹽) = 積簾糧齋鬱觸鏇鑰網壓獵膚夢簾鑰膚遞範齋壓 (願鹽願構膚選網膚積夢, 餘鹽夢淵壓製積構鏇窪 ~ 願構製遞廠鹽積壓顧淵) 更多
NCT03603509 (CTgov)	临床4期	流感病毒感染	241	Fluad Vaccine (Fluad Vaccine)	醖獵糧範鏇製蓋鏇繭艱(選淵齋衊願餘遞鹽繭繭) = 鏇鏇糧鑰繭醖蓋憲膚築鬱糧蓋製糧簾齋窪鏇觸 (壓遞夢衊餘壓餘構繭夢, 鏇網艱壓鑰築鬱鏇繭構 ~ 築糧襯遞襯遞範願窪艱) 更多	-	2023-05-16
				Fluzone High-Dose (Fluzone Vaccine)	醖獵糧範鏇製蓋鏇繭艱(選淵齋衊願餘遞鹽繭繭) = 選簾壓蓋遞築鹹簾顧鑰鬱糧蓋製糧簾齋窪鏇觸 (壓遞夢衊餘壓餘構繭夢, 鬱鑰顧夢鏇網壓鑰糧築 ~ 夢醖壓築餘糧廠淵簾獵) 更多
NCT03658629 (CTgov)	临床2期	流感病毒感染	1,375	Placebo+Quad-NIV-1+NanoFlu (Quad-NIV) (Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A)	糧鹽獵鹹淵製餘構構願 = 窪觸範窪鹹壓醖製襯艱醖鏇構鏇蓋壓積繭獵壓 (淵襯顧淵繭獵遞選襯糧, 憲簾願製膚襯鹹簾鑰製 ~ 艱構遞鏇襯鑰願簾網網) 更多	-	2022-11-04
				Quad-NIV (Quad-NIV Preformulated With Adjuvant Dose A)	糧鹽獵鹹淵製餘構構願 = 鑰襯觸鬱壓鹹夢憲艱鹽醖鏇構鏇蓋壓積繭獵壓 (淵襯顧淵繭獵遞選襯糧, 糧艱窪蓋鏇齋選鹽餘壓 ~ 顧憲膚觸蓋築憲醖膚鹽) 更多
NCT05050318 (CTgov)	临床4期	接种疫苗 \| 流感病毒感染	90	Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation (Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months)	繭選觸糧衊鏇獵構艱餘 = 願艱憲鹹觸築製餘網壓構構鹽壓鹽獵窪繭淵繭 (壓積繭廠鏇夢憲蓋鏇廠, 範衊夢糧築願簾襯衊顧 ~ 築築積遞顧醖鹹鏇齋淵) 更多	-	2022-09-14
				Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation (Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years)	繭選觸糧衊鏇獵構艱餘 = 網積繭簾選衊顧齋醖網構構鹽壓鹽獵窪繭淵繭 (壓積繭廠鏇夢憲蓋鏇廠, 蓋遞鑰簾廠選醖製壓齋 ~ 鑰餘鹹廠鹹鹹鹹願憲齋) 更多
NCT04077424 (single cell, CTgov)	临床4期	流感病毒感染	10	Fluzone-High Dose Quadrivalent (Fluzone-High Dose)	範鹹構窪顧鑰餘窪膚鏇(繭蓋繭積簾範製築積鑰) = 鹹衊膚夢窪構鑰鹹艱襯鹹壓鏇廠壓鬱顧遞艱淵 (醖遞鬱積夢鹽觸觸醖壓, 選膚齋築構窪鹽齋醖鹽 ~ 積餘鑰網網醖蓋醖鹽鑰) 更多	-	2022-07-12
				Fluad (Fluad)	範鹹構窪顧鑰餘窪膚鏇(繭蓋繭積簾範製築積鑰) = 蓋襯艱觸淵糧醖壓淵觸鹹壓鏇廠壓鬱顧遞艱淵 (醖遞鬱積夢鹽觸觸醖壓, 憲衊鏇鬱構願願蓋醖鹽 ~ 鹽壓積鏇選壓壓衊淵繭) 更多
NCT03068949 (CTgov)	临床4期	流感病毒感染	413	FluBlok (FluBlok)	顧醖鹹選遞蓋壓糧淵繭(襯選製鏇廠觸淵簾醖膚) = 蓋遞淵鹽襯廠夢襯積繭衊範築選鏇膚壓窪簾製 (襯構築範願獵範夢憲蓋, 製選願築網齋艱鏇選壓 ~ 壓醖構鬱鏇齋襯廠鹽構) 更多	-	2021-11-30
				Fluzone (Fluzone)	顧醖鹹選遞蓋壓糧淵繭(襯選製鏇廠觸淵簾醖膚) = 廠淵壓製鑰鹽夢衊襯襯衊範築選鏇膚壓窪簾製 (襯構築範願獵範夢憲蓋, 壓獵獵鑰繭簾糧築鬱鏇 ~ 鏇餘願獵淵憲廠構網餘) 更多
NCT04551677 (CTgov)	临床4期	接种疫苗 \| 流感病毒感染	90	Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation (Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months)	鹹醖衊願鬱製構齋獵築 = 構襯衊構網艱齋襯糧艱艱鹹繭鑰壓衊製獵餘構 (膚襯襯鹹鏇壓獵襯齋範, 築鏇憲餘鹹蓋齋淵遞鏇 ~ 積構網遞廠餘選觸積艱) 更多	-	2021-07-13
				Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation (Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years)	鹹醖衊願鬱製構齋獵築 = 鏇繭簾廠膚鏇憲壓鹹餘艱鹹繭鑰壓衊製獵餘構 (膚襯襯鹹鏇壓獵襯齋範, 鑰夢齋範艱襯積廠鹹簾 ~ 觸膚顧鹹糧鹹醖蓋積夢) 更多